Unusual presentation of upper urinary tract urothelial carcinoma in Taiwan: Direct comparison from Taiwan-Japan UTUC Collaboration Cohort.
Japan
Taiwan
characteristics
oncologic outcome
upper urinary tract urothelial carcinoma
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
07
10
2019
accepted:
05
01
2020
pubmed:
27
2
2020
medline:
28
4
2021
entrez:
27
2
2020
Statut:
ppublish
Résumé
To carry out a comparison of upper urinary tract urothelial carcinoma characteristics and behavior between patients in Taiwan and Japan. A Taiwan urinary tract urothelial carcinoma cohort was obtained from Kaohsiung Chang Gung Memorial Hospital, and a Japan urinary tract urothelial carcinoma cohort from Hirosaki University Hospital. The inclusion criteria were urinary tract urothelial carcinoma patients who underwent radical nephroureterectomy. Those who received perioperative chemotherapy were excluded. Finally, 765 patients in the Taiwan cohort and 325 in the Japan cohort were analyzed. The end-point of this study was to study the natural course of urinary tract urothelial carcinoma within 5 years between these two groups. The main finding was that urinary tract urothelial carcinoma patients in Taiwan were younger (P < 0.001), more were women (P < 0.001), with low-stage disease (P < 0.001), with more chronic kidney disease (P < 0.001), with less smoking history (P < 0.001), with more bladder cancer history (P = 0.002), with more multifocal (P < 0.001) and less high-grade disease (P = 0.015), as well as less lymphovascular invasion (P < 0.001) and more squamous differentiation (P < 0.001). However, the multivariate Cox regression analysis showed no racial difference in oncologic outcome, such as intravesical recurrence, systemic recurrence or cancer-specific death in primary and propensity-matched cohorts. Bladder cancer history was found to be the most important factor predicting intravesical recurrences, whereas stage was strongly associated with systemic recurrence and cancer specific mortality. The clinical characteristics of urinary tract urothelial carcinoma in Taiwan are significantly different from those of urinary tract urothelial carcinoma in Japan. However, there is no racial difference in stage-specific oncologic outcome after standard nephroureterectomy.
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
327-332Informations de copyright
© 2020 The Japanese Urological Association.
Références
Luo HL, Chen YT, Chuang YC et al. Subclassification of upper urinary tract urothelial carcinoma by the neutrophil-to-lymphocyte ratio (NLR) improves prediction of oncological outcome. BJU Int. 2014; 113: E144-9.
Xiong G, Chen X, Li X et al. Prevalence and factors associated with baseline chronic kidney disease in China: a 10-year study of 785 upper urinary tract urothelial carcinoma patients. J. Formos Med. Assoc. 2014; 113: 521-6.
Wang LJ, Chou WC, Pang ST et al. Risk stratification of upper urinary tract urothelial carcinoma patients for survival prediction: a simple summation scoring method. J. Cancer 2018; 9: 2284-94.
Momota M, Hatakeyama S, Tokui N et al. The impact of preoperative severe renal insufficiency on poor postsurgical oncological prognosis in patients with urothelial carcinoma. Eur Urol. Focus. 2019; 5: 1066-73.
Kim TH, Hong B, Seo HK et al.; Urothelial Cancer-Advanced Research and Treatment (UCART) Study Group. The comparison of oncologic outcomes between open and laparoscopic radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A Korean multicenter collaborative study. Cancer Res. Treat. 2019; 51: 240-51.
Necchi A, Lo Vullo S, Mariani L et al. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaborati. BJU Int. 2018; 121: 252-9.
Chappidi MR, Kates M, Johnson MH et al. Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population-based analysis (2004-2012). Urol Oncol. 2016; 34: 531.e15-e24.
Tan LB, Chen KT, Guo HR. Clinical and epidemiological features of patients with genitourinary tract tumour in a blackfoot disease endemic area of Taiwan. BJU Int. 2008; 102: 48-54.
Chen CH, Dickman KG, Huang CY et al. Aristolochic acid - induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int. J. Cancer 2013; 133: 14-20.
Bellmunt J, de Wit R, Vaughn DJ et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 2017; 376: 1015-26.
Chou YH, Huang CH. Unusual clinical presentation of upper urothelial carcinoma in Taiwan. Cancer 1999; 85: 1342-4.
Margulis V, Shariat SF, Matin SF et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115: 1224-33.
Chen JS, Lu CL, Huang LC et al. Chronic kidney disease is associated with upper tract urothelial carcinoma: a nationwide population-based cohort study in Taiwan. Medicine 2016; 95: e3255.
Kaag MG, O'Malley RL, O'Malley P et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur. Urol. 2010; 58: 581-7.
Maru S, Abe T, Shinohara N et al. Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic agents on the outcome of metastatic urothelial carcinoma: a retrospective study. Int. J. Urol. 2012; 19: 110-6.
Zhong W, Zhang L, Ma J et al. Impact of aristolochic acid exposure on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Onco. Targets Ther. 2017; 10: 5775-82.
Luciano RL, Perazella MA. Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment. Drug Saf. 2015; 38: 55-64.
Poon SL, Pang ST, McPherson JR et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci. Transl. Med. 2013; 5: 197ra101.
Ishioka J, Saito K, Kijima T et al. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU Int. 2015; 115: 705-12.
Seisen T, Krasnow RE, Bellmunt J et al. Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper urinary tract urothelial carcinoma. J. Clin. Oncol. 2017; 35: 852-60.
Kubota Y, Hatakeyama S, Tanaka T et al. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget 2017; 8: 101500-8.
Aziz A, Dobruch J, Hendricksen K et al. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. World J. Urol. 2017; 35: 1401-7.